Department of Cardiology, Lu'an Hospital of Anhui Medical University, Lu'an, Anhui, 237000, People's Republic of China.
Graduate School of Bengbu Medical College, Bengbu, Anhui, 233004, People's Republic of China.
J Cardiothorac Surg. 2024 Apr 5;19(1):180. doi: 10.1186/s13019-024-02699-7.
The efficacy and safety of low-pressure balloon pre-dilatation before intracoronary pro-urokinase (pro-UK) in preventing no-reflow during percutaneous coronary intervention (PCI) remains unknown. This study aimed to evaluate the clinical outcomes of intracoronary pro-UK combined with low-pressure balloon pre-dilatation in patients with anterior ST-segment-elevation myocardial infarction (STEMI).
This was a randomized, single-blind, investigator-initiated trial that included 179 patients diagnosed with acute anterior STEMI. All patients were eligible for PCI and were randomized into two groups: intracoronary pro-UK combined with (ICPpD group, n = 90) or without (ICP group, n = 89) low-pressure balloon pre-dilatation. The main efficacy endpoint was complete epicardial and myocardial reperfusion. The safety endpoints were major adverse cardiovascular events (MACEs), which were analyzed at 12 months follow-up.
Patients in the ICPpD group presented significantly higher TIMI myocardial perfusion grade 3 (TMPG3) compared to those in the ICP group (77.78% versus 68.54%, P = 0.013), and STR ≥ 70% after PCI 30 min (34.44% versus 26.97%, P = 0.047) or after PCI 90 min (40.0% versus 31.46%, P = 0.044). MACEs occurred in 23 patients (25.56%) in the ICPpD group and in 32 patients (35.96%) in the ICP group. There was no difference in hemorrhagic complications during hospitalization between the groups.
Patients with acute anterior STEMI presented more complete epicardial and myocardial reperfusion with adjunctive low-pressure balloon pre-dilatation before intracoronary pro-UK during PCI.
2019xkj213.
在经皮冠状动脉介入治疗(PCI)中,在使用组织型纤溶酶原激活剂(pro-UK)前进行低压球囊预扩张以预防无复流的疗效和安全性尚不清楚。本研究旨在评估在急性前壁 ST 段抬高型心肌梗死(STEMI)患者中应用冠状动脉内 pro-UK 联合低压球囊预扩张的临床疗效。
这是一项随机、单盲、研究者发起的试验,纳入了 179 例急性前壁 STEMI 患者。所有患者均符合 PCI 适应证,并随机分为两组:冠状动脉内 pro-UK 联合(ICPpD 组,n=90)或不联合(ICP 组,n=89)低压球囊预扩张。主要疗效终点为完全心外膜和心肌再灌注。安全性终点为主要不良心血管事件(MACEs),在 12 个月随访时进行分析。
ICPpD 组患者 TIMI 心肌灌注分级 3(TMPG3)显著高于 ICP 组(77.78%比 68.54%,P=0.013),PCI 后 30 分钟 STR≥70%(34.44%比 26.97%,P=0.047)或 PCI 后 90 分钟 STR≥70%(40.0%比 31.46%,P=0.044)的患者比例更高。ICPpD 组有 23 例(25.56%)患者和 ICP 组有 32 例(35.96%)患者发生 MACEs。两组患者住院期间出血并发症无差异。
在 PCI 中,急性前壁 STEMI 患者应用冠状动脉内 pro-UK 前进行低压球囊预扩张可获得更完全的心外膜和心肌再灌注。
2019xkj213。